These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 30857514)

  • 21. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
    Teshome BF; Vouri SM; Hampton N; Kollef MH; Micek ST
    Pharmacotherapy; 2019 Mar; 39(3):261-270. PubMed ID: 30506852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis.
    Billot L; Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Dulhunty JM;
    Crit Care Resusc; 2021 Sep; 23(3):273-284. PubMed ID: 38046078
    [No Abstract]   [Full Text] [Related]  

  • 26. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
    Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
    BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.
    Monti G; Galbiati C; Toffoletto F; Calabrò MG; Colombo S; Ferrara B; Giardina G; Lembo R; Marzaroli M; Moizo E; Mucci M; Pasculli N; Plumari VP; Scandroglio AM; Tozzi M; Momesso E; Boffa N; Lobreglio R; Montrucchio G; Guarracino F; Benedetto U; Biondi-Zoccai G; D'Ascenzo F; D'Andrea N; Paternoster G; Ananiadou S; Ballestra M; De Sio A; Pota V; Cotoia A; Della Selva A; Bruni A; Iapichino G; Bradić N; Corradi F; Gemma M; Nogtev P; Petrova M; Agrò FE; Cabrini L; Forfori F; Likhvantsev V; Bove T; Finco G; Landoni G; Zangrillo A;
    Contemp Clin Trials; 2021 May; 104():106346. PubMed ID: 33684595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
    Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
    Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
    Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
    Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
    J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of prolonged infusion of beta-lactam antibiotics in patients with sepsis: personal perspectives.
    Rafailidis PI; Falagas ME
    Expert Rev Anti Infect Ther; 2020 Oct; 18(10):957-966. PubMed ID: 32564641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
    Roberts JA; Paratz J; Paratz E; Krueger WA; Lipman J
    Int J Antimicrob Agents; 2007 Jul; 30(1):11-8. PubMed ID: 17442541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resolving the Dilemma on Continuous vs Intermittent β-Lactam Antibiotics in Sepsis.
    Wiersinga WJ; van Agtmael MA
    JAMA; 2024 Aug; 332(8):623-625. PubMed ID: 38864160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.